Tranexamic acid - Hyundai Pharmaceutical

Drug Profile

Tranexamic acid - Hyundai Pharmaceutical

Alternative Names: HTB-003

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class Antifibrinolytics; Antihaemorrhagics; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Melanosis

Most Recent Events

  • 18 Jan 2018 Discontinued - Phase-III for Melanosis in South Korea (Topical)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Dec 2015 Phase-III clinical trials in Melanosis in South Korea (unspecified route) prior to December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top